Cargando…

Joint longitudinal model-based meta-analysis of FEV(1) and exacerbation rate in randomized COPD trials

Model-based meta-analysis (MBMA) is an approach that integrates relevant summary level data from heterogeneously designed randomized controlled trials (RCTs). This study not only evaluated the predictability of a published MBMA for forced expiratory volume in one second (FEV(1)) and its link to annu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Llanos-Paez, Carolina, Ambery, Claire, Yang, Shuying, Beerahee, Misba, Plan, Elodie L., Karlsson, Mats O.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2023
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374752/ https://www.ncbi.nlm.nih.gov/pubmed/36947282 http://dx.doi.org/10.1007/s10928-023-09853-z

Ejemplares similares

Improved Confidence in a Confirmatory Stage by Application of Item-Based Pharmacometrics Model: Illustration with a Phase III Active Comparator-Controlled Trial in COPD Patients
por: Llanos-Paez, Carolina, et al.
Publicado: (2022)

Improved Decision-Making Confidence Using Item-Based Pharmacometric Model: Illustration with a Phase II Placebo-Controlled Trial
por: Llanos-Paez, Carolina, et al.
Publicado: (2021)

A Novel Method for Analysing Frequent Observations from Questionnaires in Order to Model Patient-Reported Outcomes: Application to EXACT® Daily Diary Data from COPD Patients
por: Germovsek, Eva, et al.
Publicado: (2019)

Bayesian approach to investigate a two-state mixed model of COPD exacerbations
por: Largajolli, Anna, et al.
Publicado: (2019)

Correction to: Bayesian approach to investigate a two-state mixed model of COPD exacerbations
por: Largajolli, Anna, et al.
Publicado: (2019)

Longitudinal FEV(1) and Exacerbation Risk in COPD: Quantifying the Association Using Joint Modelling
por: Zhudenkov, Kirill, et al.
Publicado: (2021)

Longitudinal change of FEV(1) and inspiratory capacity: clinical implication and relevance to exacerbation risk in patients with COPD
por: Jo, Yong Suk, et al.
Publicado: (2019)

Detecting placebo and drug effects on Parkinson's disease symptoms by longitudinal item‐score models
por: Chen, Chao, et al.
Publicado: (2021)

Dose response of umeclidinium administered once or twice daily in patients with COPD: a randomised cross-over study
por: Church, Alison, et al.
Publicado: (2014)

Item Response Model Adaptation for Analyzing Data from Different Versions of Parkinson’s Disease Rating Scales
por: Gottipati, Gopichand, et al.
Publicado: (2019)

Effects of Vitamin D Intake on FEV1 and COPD Exacerbation: A Randomized Clinical Trial Study
por: Zendedel, Abolfazl, et al.
Publicado: (2015)

Reliability of FEV(1)/FEV(6) to Diagnose Airflow Obstruction Compared with FEV(1)/FVC: The PLATINO Longitudinal Study
por: Perez-Padilla, Rogelio, et al.
Publicado: (2013)

Variability of FEV(1) and Criterion for Acute Pulmonary Exacerbation
por: Jenkins, Bradlee A., et al.
Publicado: (2014)

Diagnosis, assessment, and phenotyping of COPD: beyond FEV(1)
por: Lange, Peter, et al.
Publicado: (2016)

COPD assessment test and FEV(1): do they predict oxygen uptake in COPD?
por: Carvalho-Jr, Luiz Carlos S, et al.
Publicado: (2018)

Association Between Vitamin D Levels and FEV1, Number of Exacerbations, and CAT Score in Stable COPD Patients in Indonesia
por: Soeroto, Arto Yuwono, et al.
Publicado: (2021)

Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium/Vilanterol via a Single Inhaler in Patients with COPD
por: Mehta, Rashmi, et al.
Publicado: (2018)

COPD exacerbations and patient-reported outcomes according to post-bronchodilator FEV(1) – a post-hoc analysis of pooled data
por: Chai, Chee-Shee, et al.
Publicado: (2023)

Annual decline rate in FEV1s in community-dwelling older adults diagnosed with mild to moderate COPD
por: Rosso, Aldana, et al.
Publicado: (2022)

Inflammatory and immunological profiles in patients with COPD: relationship with FEV (1) reversibility
por: Queiroz, Cleriston Farias, et al.
Publicado: (2016)

Low FEV1 Is Associated With Increased Risk Of Cachexia In COPD Patients
por: Mokari-Yamchi, Amin, et al.
Publicado: (2019)

Pulmonary function testing in COPD: looking beyond the curtain of FEV1
por: Kakavas, Sotirios, et al.
Publicado: (2021)

FVC, but not FEV(1,) is associated with clinical outcomes of asthma-COPD overlap
por: An, Tai Joon, et al.
Publicado: (2022)

Routine spirometry in cystic fibrosis patients: impact on pulmonary exacerbation diagnosis and FEV(1) decline
por: de Aquino, Carolina Silva Barboza, et al.
Publicado: (2022)

Fixed Cut-Off for FEV1/FEV6 and FEV6 in Detection of Obstructive and Restrictive Patterns
por: Aghili, Rokhsareh, et al.
Publicado: (2013)

Beyond FEV(1) in COPD: a review of patient-reported outcomes and their measurement
por: Jones, Paul, et al.
Publicado: (2012)

Risk factors for FEV(1) decline in mild COPD and high-risk populations
por: Chen, Shujing, et al.
Publicado: (2017)

Lower FEV(1) in non-COPD, nonasthmatic subjects: association with smoking, annual decline in FEV(1), total IgE levels, and TSLP genotypes
por: Masuko, Hironori, et al.
Publicado: (2011)

Rate of Decline of FEV(1) as a Biomarker of Survival?
por: Papi, Alberto, et al.
Publicado: (2021)

Decline in FEV(1) and hospitalized exacerbations in individuals with severe alpha-1 antitrypsin deficiency
por: Hiller, Adriana-Maria, et al.
Publicado: (2019)

Evaluating FEV1 decline in diagnosis and management of pulmonary exacerbations in children with cystic fibrosis
por: Bouzek, Drake C., et al.
Publicado: (2022)

Median regression spline modeling of longitudinal FEV(1) measurements in cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) patients
por: Conrad, Douglas J., et al.
Publicado: (2017)

Comparison of the variability of the annual rates of change in FEV(1) determined from serial measurements of the pre- versus post-bronchodilator FEV(1) over 5 years in mild to moderate COPD: Results of the lung health study
por: Tashkin, Donald P, et al.
Publicado: (2012)

Sputum cell counts to manage prednisone-dependent asthma: effects on FEV(1) and eosinophilic exacerbations
por: Aziz-Ur-Rehman, Afia, et al.
Publicado: (2017)

Bronchodilator Response of FEV6 and FEV3 as Surrogates of Forced Vital Capacity
por: Mehrparvar, Amir Houshang, et al.
Publicado: (2014)

Genome organization and molecular characterization of the three Formica exsecta viruses—FeV1, FeV2 and FeV4
por: Dhaygude, Kishor, et al.
Publicado: (2019)

Estimation of TGF-β1 genotypes in Egyptian smokers; association with FEV(1) in COPD patients
por: Bohy, Mohammad El, et al.
Publicado: (2010)

A novel CT-emphysema index/FEV(1) approach of phenotyping COPD to predict mortality
por: Loh, Li-Cher, et al.
Publicado: (2018)

Changes in FEV(1) over time in COPD and the importance of spirometry reference ranges: the devil is in the detail
por: Kirkby, Jane, et al.
Publicado: (2019)

A blood and bronchoalveolar lavage protein signature of rapid FEV(1) decline in smoking-associated COPD
por: DiLillo, Katarina M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_f2orct6pej9i6ig61n56rnesro